Evidence map›Paper›PMID 35281001›Full record

ArticleFrontiers in immunology2022

Low-Dose 5-Aza and DZnep Alleviate Acute Graft-

Qing Ya Wang, Hui Hui Liu, Yu Jun Dong, Ze Yin Liang, Yue Yin, Wei Liu, Qing Yun Wang, Qian Wang, Yu Hua Sun, Wei Lin Xu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Qing Ya WangDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Hui Hui LiuDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Yu Jun DongDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Ze Yin LiangDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Yue YinDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Wei LiuDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Qing Yun WangDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Qian WangDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Yu Hua SunDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Wei Lin XuDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Na HanDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Yuan LiDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Han Yun RenDepartment of Hematology, Peking University First Hospital, Peking University, Beijing, China.
Peking University First Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Previous studies showed that hypomethylating agents (HMAs) could alleviate acute graft- Methods: We first optimized the concentrations of individual and combinational 5-Aza and DZNep treatments to ensure no obvious toxicities on activated T cells by evaluating T-cell proliferation, viability, and differentiation. A mouse model of aGvHD was then established to assess the prophylactic efficacy of 5-Aza, DZNep, and their combination on aGvHD. The immunomodulatory effect on T cells and the hematopoietic reconstruction were assessed. Additionally, RNA sequencing (RNA-seq) was performed to identify the underlying molecular mechanisms. Results: Compared with single treatments, the Conclusion: The combination of 5-Aza and DZNep could enhance the prophylactic effect for aGvHD by influencing donor T-cell differentiation through affecting cytokine and chemokine pathways. This study shed light on the effectively prophylactic measure for aGvHD using different epigenetic agent combinations.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdenosineAnimalsCytokinesDisease Models, AnimalHematopoiesisHistone MethyltransferasesMice3-deazaneplanocinAdenosineCytokinesHistone Methyltransferasesacute graft-versus-host disease (aGvHD)epigenetichistone modificationhypomethylation agentsmouse model

Identifiers

PMID35281001
PMCPMC8907421
OpenAlexW4213455657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.